AstraZeneca PLC (AZN)vsViking Holdings Ltd (VIK)
AZN
AstraZeneca PLC
$188.42
+2.74%
HEALTHCARE · Cap: $290.12B
VIK
Viking Holdings Ltd
$68.58
-4.20%
CONSUMER CYCLICAL · Cap: $32.40B
Smart Verdict
WallStSmart Research — data-driven comparison
AstraZeneca PLC generates 803% more annual revenue ($58.74B vs $6.50B). VIK leads profitability with a 17.6% profit margin vs 17.4%. VIK trades at a lower P/E of 28.3x. VIK earns a higher WallStSmart Score of 66/100 (B-).
AZN
Strong Buy66
out of 100
Grade: B-
VIK
Strong Buy66
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+32.7%
Fair Value
$305.60
Current Price
$188.42
$117.18 discount
Margin of Safety
+36.3%
Fair Value
$120.28
Current Price
$68.58
$51.70 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Earnings expanding 53.9% YoY
Every $100 of equity generates 23 in profit
Strong operational efficiency at 21.6%
Generating 1.4B in free cash flow
Strong operational efficiency at 20.9%
Revenue surging 27.8% year-over-year
Areas to Watch
Moderate valuation
4.1% revenue growth
Distress zone — elevated risk
Moderate valuation
2.3% earnings growth
ROE of 2.5% — below average capital efficiency
Trading at 28.0x book value
Comparative Analysis Report
WallStSmart ResearchBull Case : AZN
The strongest argument for AZN centers on Market Cap, EPS Growth, Return on Equity. Profitability is solid with margins at 17.4% and operating margin at 21.6%.
Bull Case : VIK
The strongest argument for VIK centers on Operating Margin, Revenue Growth. Profitability is solid with margins at 17.6% and operating margin at 20.9%. Revenue growth of 27.8% demonstrates continued momentum.
Bear Case : AZN
The primary concerns for AZN are P/E Ratio, Revenue Growth, Altman Z-Score.
Bear Case : VIK
The primary concerns for VIK are P/E Ratio, EPS Growth, Return on Equity.
Key Dynamics to Monitor
AZN profiles as a value stock while VIK is a growth play — different risk/reward profiles.
VIK is growing revenue faster at 27.8% — sustainability is the question.
AZN generates stronger free cash flow (1.4B), providing more financial flexibility.
Monitor DRUG MANUFACTURERS - GENERAL industry trends, competitive dynamics, and regulatory changes.
Bottom Line
AZN scores higher overall (66/100 vs 66/100), backed by strong 17.4% margins. VIK offers better value entry with a 36.3% margin of safety. Both earn "Strong Buy" and "Strong Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
AstraZeneca PLC
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
AstraZeneca PLC discovers, develops, manufactures and markets prescription drugs in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infections, neuroscience and gastroenterology worldwide. The company is headquartered in Cambridge, the United Kingdom.
Viking Holdings Ltd
CONSUMER CYCLICAL · TRAVEL SERVICES · USA
Viking Holdings Ltd engages in the passenger shipping and other forms of passenger transport in North America, the United Kingdom, and internationally. The company is headquartered in Pembroke, Bermuda.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?